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List of abbreviations 
 
ABO             Blood groups A, B and O 
APGAR       Appearance, Pulse, Grimace, Activity and Respiration 
GSH            Groote Schuur Hospital 
HPLC          High Performance Liquid Chromatography 
ICU             Intensive Care Unit 
RBC             Red Blood Cell 
TcB             Transcutaneous Bilirubin 
TSB             Total Serum Bilirubin 







































Definition of terms 
	  
Neonate: An infant from birth to 28 days of age. 
	  
Preterm Neonate: Neonate delivered before 37 completed weeks of gestation. 
 
Neonatal jaundice: Yellow discoloration of the skin of a neonate. 
 
Total Serum Bilirubin: Bilirubin level determined by performing a blood test 
 





















































Neonatal jaundice is one of the most common clinical signs encountered among newborn 
babies. It results from deposition of bilirubin (yellow pigment) in the skin and mucus 
membranes. The main source of bilirubin is the breakdown of red blood cells in the 
reticuloendothelial system. Bilirubin is transported to the liver where it is conjugated to a 
water soluble product that is easily excreted. Immaturity of the neonatal liver enzyme system 
is the main factor placing them at risk of developing jaundice 1-4. 
Unconjugated bilirubin has been noted to cross the blood-brain barrier, causing 
encephalopathy in the immediate period, and potential for long term choreoarthetoid cerebral 
palsy and other complications. 4-7. The mainstays in preventing and managing bilirubin 
encephalopathy are the use of phototherapy and exchange transfusion which have been 
subjects of rigorous investigation over the last 60-70years 8,9.  
The need to prevent bilirubin induced neurologic damage necessitates repeated blood 
withdrawal in order to ascertain bilirubin levels. Non-invasive, painless screening by use of 
transcutaneous bilirubinometry is becoming more acceptable especially for term and near 
term neonates 10,11. However, for preterm neonates the use of transcutaneous bilirubinometry 
is still under scrutiny. 
Transcutaneous bilirubin measuring devices have undergone modifications to enable them to 
overcome previous inconsistency of results in lower gestational ages and different skin 
pigmentations. Studies have shown the results from newer generation devices correlate well 
with serum bilirubin irrespective of skin pigmentation 12-14 but with respect to gestational age 
the findings are divergent 15-17.  
Some studies among preterm neonates show acceptable correlation between transcutaneous 
and serum bilirubin levels 18-20but no such study has been conducted in South Africa. The 














bilirubin levels among preterm neonates <35weeks gestational age and its utility as a 
screening tool in the South African preterm population.  
Literature review 
Epidemiology of neonatal jaundice 
Neonatal jaundice is a frequently observed sign. It occurs in 60% of term newborn infants 
and 80% of preterm infants during the first week of life 11. 
Pathogenesis of neonatal jaundice 
When red blood cells breakdown; the haemoglobin released is split into heme and globulin. 
The heme molecule is oxidised to iron and biliverdin by the enzyme heme oxygenase in the 
reticuloendothelial system. Biliverdin is then reduced to bilirubin by the enzyme biliverdin 
reductase. The bilirubin produced is transported to the liver tightly but reversibly bound to 
albumin 3,21,22.  
At the hepatocyte, bilirubin is released from the albumin and is taken up by ligandin. 
Bilirubin is then conjugated to bilirubin mono- then diglucoronide by the enzyme uridine 
diphosphoglucoronyl transferase (UDPGT). This product is water soluble, and is secreted 
into bile 1,3,23.  
Conjugated bilirubin in the gut is reduced by intestinal flora to urobilinogen and a small 
amount is hydrolysed by intestinal β-glucoronidase to unconjugated bilirubin which may get 
reabsorbed. Neonates especially those exclusively breast feeding have increased activity of β-
glucoronidase 24. 
 There are many factors that predispose newborn infants to neonatal jaundice. Firstly, 
neonates produce bilirubin at a rate of 8-10mg/kg/24hours compared to adults 3-
4mg/kg/24hours yet the liver enzyme system necessary for conjugation of bilirubin in the 
newborn is only 1% of adult level 1,25. Apart from newborn babies having very low levels of 
UDPGT and increased β glucoronidase activity, they also have higher haemoglobins. These 














half-life of 90 days 26. There is also an increased entero-hepatic circulation as a result of low 
volume of feeds 27,28. 
When the amount of bilirubin produced is greater than what the liver can conjugate and 
albumin can bind, the free lipid soluble unconjugated bilirubin easily crosses biological 
membranes and accumulates in the skin giving the yellow discoloration4. Unconjugated 
bilirubin also crosses the blood-brain barrier and at high levels is neurotoxic 4,7,29. 
Although the majority of neonates develop physiological jaundice due to the reasons 
discussed above, some newborns develop pathological jaundice from secondary causes. 
These include haemolysis of red blood cells due to blood group incompatibility, sepsis, 
enzyme deficiency (G6PD, pyruvate kinase), RBC membranopathy, and hemoglobinopathies. 
Other conditions such as Crigler Najjar syndrome and, hypothyroidism, may impair 
conjugation whilst intrinsic liver pathology and obstructive conditions such as biliary atresia, 
would increase the level of congujated bilirubin. 
Bilirubin measurement 
Different methods of estimating the amount of bilirubin in the serum have been developed. 
The gold standard is the use of high performance liquid chromatography (HPLC), this 
method is not used routinely in laboratories but reserved mainly for research laboratories 3. 
The traditional method used in laboratories is the diazo method. This involves reacting serum 
with diazo reagent and then through spectrophotometry the levels of direct and indirect 
bilirubin are determined 3. 
Non-invasive methods 
Visual assessment 
This was the first non-invasive way of jaundice assessment to be described. It was noted as 
early as 1940 that the level of jaundice correlated with the serum bilirubin but it was easy to 
miss infants with high levels of bilirubin. Studies have noted that there is cephalo-caudal 














estimated bilirubin levels for different body parts was developed in 1969. Although this scale 
was developed there were wide bilirubin ranges for each zone 30. 
Colour scale (icterometer) 
In the early 60’s an icterometer which constituted a strip with different shades of yellow was 
developed to which the infants’ skin colour was compared 31,32.  
Transcutaneous bilirubinometry 
Using the principle of reflectance of light, a handheld device that generates light, was 
developed. It transilluminates the subcutaneous tissue then absorbs the reflected light and 
transmits it through a spectrophotometric module to measure the intensity of yellowness. This 
intensity can be used to estimate the amount of bilirubin in the skin. These devices have 





























Preterm neonates are at increased risk for bilirubin encephalopathy and kernicterus 2. The 
need to prevent these necessitates repeated blood withdrawals to determine bilirubin level in 
order to monitor levels. This process involves inflicting pain and distress to the neonate, it 
also places the neonate at risk for cellulitis and osteomyelitis from heel pricks as well as 
anaemia from blood withdrawals.  
In our institution, routine total serum bilirubin is ordered at six hours of age among all 
neonates born to rhesus negative and group O positive mothers. This is also done at any age if 
any neonate appears clinically jaundiced. This constitutes a large workload for the nursing, 
clinical and laboratory staff as well as being a considerable financial cost for the institution. 
Repeated total serum bilirubin measurement is costly, sometimes unnecessary, and the results 
are only obtained several hours after taking the specimen. There is risk of mislabelling or 
misplacing the specimen. All the above might be solved by a non-invasive, point-of-care 
technique like the transcutaneous bilirubinometer if its performance correlates well with the 























Transcutaneous bilirubin measurement is a non-invasive, painless, and blood sparing 
procedure which yields results promptly. 
Findings from different studies have revealed transcutaneous bilirubin measurement to be 
cheaper compared to serum bilirubin measurement and its use as a screening tool has been 
shown to reduce number of blood withdrawals for bilirubin level measurement 14,18,35. This 
minimizes pain, risk of infection and blood loss for the preterm neonate. 
Studies from different parts of the world have shown acceptable correlation between 
transcutaneous and serum bilirubin level among preterm neonates 18-20 but further studies for 
preterm infants have been recommended by organizations such as the American Academy of 
Paediatrics.  
Furthermore, no study among preterm neonates has been conducted in South Africa, and it is 






























This will be a cross sectional study among preterm neonates less than 35 weeks of gestational 
age admitted to the Nursery at Groote Schuur Hospital. 
Study setting 
This study will be conducted at Groote Schuur Hospital Nursery. 
Groote Schuur Hospital is a tertiary level teaching hospital in Cape Town South Africa and a 
teaching hospital for the University of Cape Town. It is a referral hospital for the Western 
Cape Province. 
The nursery is level III care unit with 8 ICU spaces, 12 high care spaces, 20 observational 
care spaces, 10 special care space, 15 pre-Kangaroo mother care spaces and 10 kangaroo 
mother care (KMC) spaces. The nursery on average admits 200 neonates per month with 10% 
of admission constituting neonates < 1500g.  
Serum bilirubin is ordered at 6 hours of age among all neonates born to Rhesus negative 
mothers and blood group O positive mothers and also among all neonates who clinically 
appear jaundiced. From review of records 94% of neonates weighing <1500g admitted to the 
nursery will have their serum bilirubin determined for one of the above reasons. 
A sample for serum bilirubin is obtained by heel prick. This is routinely done by the nurses 
who are mandated to order the test if the neonate fulfils any of the above criteria. The nursery 
















i) How does transcutaneous bilirubin measurement compare to serum bilirubin measurement 
among preterm neonates < 35weeks admitted to Groote Schuur Hospital nursery? 
ii) To what extent can transcutaneous bilirubin measurement among preterm neonates < 35 
weeks gestational age be used to decide on initiating phototherapy? 
Objectives of the study 
Primary objective: 
To determine how transcutaneous bilirubin (TcB) levels relate to total serum bilirubin (TSB) 
levels in preterm neonates not under phototherapy. 
Secondary objectives  
i) To determine how transcutaneous bilirubin levels would influence decision to start 
phototherapy. 
ii) To determine how skin colour, site of transcutaneous bilirubin measurement and 
gestational age influence the correlation between the two methods.                         
Study population: 
All preterm neonates < 35weeks by gestational age admitted to the nursery of Groote Schuur 
hospital. 
Inclusion criteria: 
i) Preterm neonate less than 35weeks gestational age and less than 7 days old. 
ii) Preterm neonate less than 35weeks gestational age whose TSB  has been ordered. 
Exclusion criteria: 
i) Preterm neonate who is oedematous 
ii) Preterm neonate with poor perfusion (capillary refill >3seconds) 














Sample Size estimation: 
Sample size needed to determine the correlation between TcB and TSB:  
Hypothesis test:  
Null hypothesis (H0): p = 0 
Alternative Hypothesis: p< >0 
Alpha (α): 0.05 
Power (1-β): 0.9 
 
Effect Size: As determined by Jacob Cohen in A Power Primer. 
Results for an effect size using correlation obtained from earlier study of 0.7936 
  
  RESULTS for double sided 
Alpha Power 
0.6 0.7 0.8 0.9 
0.1 8 9 11 14 
0.05 9 11 13 17 
0.01 13 16 18 23 
0.001 19 22 26 31 
 
The sample size required is 17. 
  
Sample size needed to plot Bland-Altman plot 37 
Bland-Altman plots are used to determine agreement between two measurement methods. 
The difference between TcB and TSB (di = TcB - TSB) is plotted against the mean (M = 














If we assume the differences between TcB and TSB have a normal distribution, for this study 
the difference in upper and lower limit of TcB measured to which intervention will not defer 
is considered to be +/- 20µmol/l (1.17mg/dl), this is the limit of agreement (LOA) between 
the tests. This assumption is based on the fact that at GSH if TSB is > 20µmol/l below the 
photo-line then phototherapy is not initiated.  
The tolerance interval factor : 
 
LOA = 20µmol/l (1.17mg/dl) 
Standard deviation = 1.9, 1.3 and 1.6 for 24-28weeks, 29-30weeks and 31-34weeks 
Alpha 0.05 
                                   (24-28weeks) = 1.17      =   0.67  
                                                                   1.9 
 
                                   (29-30weeks) = 1.17      =   0.9 
                                                                 1.3 
 
                                  (30-34weeks) = 1.17       = 0.73 
                                                                  1.6 
 
With reference to table of tolerance factor for normal distribution the  value yields sample 
size of > 50 for all. 
Sample size estimation for ROC, positive and negative predictive values 
According to ET Schmidt findings, the correlation between TcB and TSB ranged from 0.79 
to 0.92, and sensitivity ranged from 0.67 to 1.0 36 assuming a correlation between TcB and 














need to start photo therapy with 95% confidence, the sample size need to demonstrate this 
with power of 90% is 
    TsB   
  Outcome Y N   
TcB 
Y 50 12 62 
N 12 48 60 
    62 60 122 
 
A total of 122 preterm neonates will have to be enrolled. 




Data capturing sheets will be used to capture baseline information including mode of 
delivery, cause for preterm delivery, gestational age, birth weight, skin colour and age when 
TSB and TcBs were determined. TcB and TSB levels, phototherapy and exchange transfusion 
line will also be entered into the data capturing sheet. 
Study Procedure 
Screening and enrolment:  Written consent will be obtained from parents of preterm neonates 
who meet the inclusion criteria. Transcutaneous bilirubin will be measured within 30 minutes 
of blood collection for TSB using JM 103® equipment on forehead, chest (over the sternum) 
and interscapular region of the baby.  
Neonates’ gestational age as determined by early ultra sound (< 20 weeks) if available or by 














phototherapy and exchange transfusion line at time of transcutaneous measurement will be 
entered in a data capturing sheet.  
Specimen collection and TSB measurement: Using aseptic technique, 0.5ml of blood will be 
collected via heel prick and sent to the laboratory promptly. Using the diazo method, the level 
of serum bilirubin will be determined. 
Patient management: Study participants will be managed in accordance with the units’ 
protocol. Phototherapy will be initiated based on total serum bilirubin levels.  
Data management and analysis 
Data collecting sheet will be checked for completeness and stored securely in a locker. 
Data from the collecting sheet will be entered into a computer using Microsoft Excel 2012 
package. It will then be exported into statistical programme STATA version 11 software 
package for analysis with the help of a statistician. 
Continuous variables (age, sex, gestational age, birth weight e.t.c) will be summarized as 
mean, median and standard deviation. A table of baseline characteristics will be generated.  
Data will be stratified by gestational age and to measure the relation between TcB and TSB. 
The correlation coefficient will be computed, a scatter plot for TcB from different sites will 
be plotted against TSB, and absolute difference between TcB and TSB will be computed.  
The sensitivity, specificity, negative and positive predictive value, likelihood ratios, and area 
under the receiver operator curve of TcB will be computed utilising the photo-line and TSB 
result.  
Quality Control 
Data collecting sheet will be pretested prior to commencement of study. On commencement 
the data collecting sheet will be checked daily for completeness. Transcutaneous 














instructions. The principal investigator will ensure that TcB measurements are done within 30 
minutes of blood collection for TSB, and will also ensure that blood collected for TSB is sent 
to the laboratory promptly and personally follow-up on the results.  
A log book will be in place to enter all neonates enrolled. This will help prevent a neonate 
being tested more than once.  
Ethical consideration 
The findings of this study are aimed at improving neonatal care by minimizing pain and other 
complications of heel pricks. It would also hopefully, minimize the risks of needle stick 
injury to the health care workers and decrease the overall cost of neonatal care.  
Approval to conduct this study will be sought from the institution Research and Ethics 
committees (Human Research and Ethics Committee HREC).  
For preterm neonates who meet inclusion criteria, a detailed explanation of the procedure will 
be given to parents by the principal investigator and a translator in the event that parents do 
not understand English. Written consent will be sought from them.  
Dissemination of results 
Results of this study will be submitted to the School of Graduate Studies at University of 
Cape Town. Copies will be submitted to the School of Child and Adolescent Health (SCAH), 








































OBJECTIVES OF LITERATURE REVIEW 
The objectives of this review were to examine the performance of transcutaneous 
bilirubinometry in preterm infants by: 
1. Identifying literature on non-invasive bilirubinometry and the mechanisms by which 
they operate. 
2. Identifying literature on transcutaneous bilirubinometry among preterm neonates. 
3. Identifying knowledge gaps with respect to transcutaneous bilirubinometry in preterm 
neonates. 
 
LITERATURE SEARCH STRATEGY 
A comprehensive literature search was undertaken through PUBMED and the Cochrane 
library. The key search words used were: jaundice, transcutaneous bilirubin, preterm neonates 
and non-invasive bilirubin estimation.  
For transcutaneous bilirubin estimation, the search was restricted to preterm neonates not 
under phototherapy, late preterm neonates were excluded. Studies that had a combination of 
children under phototherapy and those not under phototherapy were included only if during 
analysis they made this distinction.  
Only literature where the two common transcutaneous bilirubinometers (Bilicheck and 
Minolta JM 103®) were used, was included. No year limit was set for the search.   
Standard Neonatology text books and up-to-date information were used mainly for literature 



















Description of the problem 
Neonatal jaundice results from deposition of bilirubin (yellow pigment) to the skin and 
mucus membranes. The main source of bilirubin is the breakdown of red blood cells in the 
reticuloendothelial system. Bilirubin is transported to the liver where it is conjugated to a 
water soluble product that is easily excreted. The ability of the newborn to clear bilirubin is 
diminished due to a deficiency of the glucoronyl transferase enzyme which is only about 1% 
of the adult level on day 7 of life and even less before this 3,39,40.  
Unconjugated bilirubin is known to cross the blood-brain barrier where it induces 
neurotoxicity and encephalopathy in the immediate period, and possible choreoarthetoid 
cerebral palsy or other complications in the long term 5-7,41. 
Types of intervention 
Bilirubin induced neurotoxicity can usually be prevented through the use of phototherapy 
which is known to convert unconjugated bilirubin by photo isomerization, photo oxidation 
and structural isomerization into more water soluble products 4,8,42. 
At much higher serum bilirubin levels, exchange transfusion is the modality of choice. 
Exchange transfusion works by removing unconjugated bilirubin from circulation and also 
through the removal of maternal antibodies which may break down red blood cells 9,43,44.  
Other modalities of treatment which include the use of intravenous immunoglobulin, tin 
protoporphyrin and clofibrate are not relevant for this review 45. 
 
Diagnosis of high serum bilirubin levels 
Phototherapy and exchange transfusion thresholds have evolved over time and include the 
Bhutani bilirubin centile charts and the South African modified chart 46-48. However, the most 














The gold standard method of establishing total serum bilirubin level is through 
chromatographic analysis such as high performance liquid chromatography (HPLC) and 
reflectancy fluorometry 49,50. These methods are usually reserved for research purposes. 
Under routine clinical conditions, the diazo method is used and results from this method have 
been noted to vary marginally from those of HPLC 51-53. 
The quest for a non-invasive method of bilirubin measurement has been on going. The 
Kramers head to toe prediction using visual inspection 30 was among the first modalities to be 
developed but it was replaced by an icterometer method that uses a strip with different hues 
of yellow for comparison 32.  
The visual methods have been discouraged 11 for their inaccuracies and have been overtaken 
by more objective methods that use skin reflectancy of light and analysis in a 
spectrophotometer 33.  
How do the transcutaneous bilirubinometers work 
One of the objectives of this literature search was to understand how transcutaneous 
bilirubinometers operate. The two commonly used transcutaneous bilirubinometer are the 
Bilicheck and the Minolta JM 103® bilirubinometer. 
The concept behind these transcutaneous bilirubinometers is light reflectancy; the 
subcutaneous tissue is trans-illuminated and light is reflected back to the machine. The 
reflected light is carried by a fibre optic bundle to a spectrophotometer where it is split into a 
spectrum and absorption at different spectra correct for the haemoglobin level. The amount of 

















Description of the studies 
Eleven studies were identified; six of these met the inclusion criteria. Majority of the studies 
were conducted in European countries and one study was conducted in The United States of 
America. No study conducted in Africa on this subject was identified. The sample size in the 
included studies ranged from 24 to 340 preterm neonates.  
Five studies were excluded; one used bilimed device55, one assessed babies under 
phototherapy56, one combined population of ill term and preterm neonates during analysis57 
 and two used the Minolta JM 102 bilirubinometer 58,59an older version of the JM 103® 
bilirubinometer. 
Findings from the included studies 
Table 1 shows summary of studies that were included in this literature review. 
What all the included studies show is a statistically significant correlation coefficient between 
transcutaneous bilirubin and serum bilirubin among preterm neonates. Some studies found 
better correlation with lower gestational age 19,36 with one finding the opposite 15. 
Three studies looked at the influence of postnatal age on correlation coefficient between 
transcutaneous and serum bilirubin. Knupfer and Schmidt et al 15,36 reported no effect while 
Ebbesen et al reported no difference with the Bilicheck but with the Minolta JM 103® 
postnatal age was found to be a confounder 60. 
Two studies looked at the relation between correlation coefficient and ethnicity; Schmidt et al 
with 16 African American infants included found no association36 and Ebbesen et al with 
only 6 Africans included in their study reported no association while using Bilicheck but 





























-r 0.73 (p < 0.05) among infants not on phototherapy. 
-Correlation was poor at low gestational age 
-Mean difference TSB and TcB: 14.4±49.1µmol/l 
- to start phototherapy sensitivity 88%, specificity 89%, NPV 
97.4%, PPV 62.2% 
-Reliability- good among > 30weeks 
 







-r 0.86 (p < 0.001) 
-Mean difference TSB and TcB: 
                      Good skin: 2.42± 19.56µmol/l 
                      Poor skin: 12.25± 32.28µmol/l 
 







-r 0.795 (p <0.001) 
- Mean difference: TSB and TCB:18.1 ± 34.2 µmol/l 
-TcB overestimated TSB in 61.5% 
-Negative predictive value ranged from 97.2% - 99.6% 
 







-r head:0.9, sternum:0.84, abdomen:0.8 (p<0.001) 
-Forehead underestimates while abdomen overestimates 
serum bilirubin. 







-Mean difference  TSB and TcB:13.6 ±B32.3µmol/l 
Ebbesen et al 
200860 
 




-r bilicheck: 0.83, Minolta: 0.86 
-Minolta underestimated TSB for almost all cases while 
Bilicheck underestimated at high TSB levels 
r: correlation coefficient 
TSB: total serum bilirubin 
TcB: Transcutaneous bilirubin 
PPV: positive predictive value 
NPV: Negative predictive value 
 
Four of these studies compared how transcutaneous bilirubin measurements estimated serum 














overestimate serum levels 17  while the other three reported a tendency to underestimate 
19,36,60.  
Only one study looked at different body sites and found transcutaneous bilirubin from the 
forehead tends to underestimate, while sternum sites were closer to serum levels. Abdominal 
readings tended to overestimate serum bilirubin levels 19. 
From these studies it seems that the correlation of transcutaneous and serum bilirubin vary 
depending on the site from which they are taken and the gestational age of the neonate. One 
possible explanation is the deposition of subcutaneous tissue.  
A literature search on deposition of subcutaneous fat in the fetus elaborated on the 
interscapular site as one of the sites where there is early deposition 61. No studies in my 
literature search had explored this site for transcutaneous bilirubinometry.  
Also from my literature search I found no study has been conducted in South Africa with 
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Background: High levels of unconjugated bilirubin in the newborn can cause brain injury. 
To prevent this; repeated blood withdrawals are necessary to ascertain bilirubin levels and 
institute care. Non-invasive, painless and bloodless screening through transcutaneous 
bilirubinometry is the standard of care for term and near term neonates but among preterm 
neonates this is under scrutiny. 
Objective: The aim of this study was to determine how transcutaneous bilirubin (TcB) level 
relates to total serum bilirubin (TSB) level among preterm neonates at Groote Schuur 
Hospital Nursery. 
Design: This was a cross sectional study. 
Methods: Over a 5 months period 122 consecutive preterm neonates < 35 weeks gestational 
age were enrolled. TcB’s were measured over the forehead, sternum and interscapular area. 
Pearson correlation coefficients and differences between TSB and TcB’s were computed. P 
value <0.05 was considered significant and confidence interval of 95% was used. 
Results: The median gestational age of study participants was 31 weeks (range: 24-34 
weeks), the median TSB level was 81.5µmol/l (range: 25-229µmol/l) and 45% had TSB at 
phototherapy threshold. The correlation coefficients for TcB’s ranged from 0.859 to 0.929 
(p<0.001). The difference between TSB and TcB’s ranged from -86 to +51µmol/l. With 
respect to initiating phototherapy, the interscapular site had the highest sensitivity (93.9%) 
and lowest false negative rate (6.06%). Interscapular TcB cutoff value of 52umol/l could 
identify accurately neonates needing phototherapy with sensitivity of 95.5% and specificity 
of 35.7%.  
Conclusion: TcB’s from the sites assessed correlated significantly with TSB. Interscapular 















Neonatal jaundice is one of the most common clinical signs encountered among newborn 
babies. Immaturity of the liver enzyme system among neonates is the main factor 
predisposing them to developing jaundice 1-4.  
Unconjugated bilirubin can cross the blood-brain barrier and induce encephalopathy acutely 
and in the long term survivors’ possible cerebral palsy 4-7. The need to prevent this 
necessitates repeated blood withdrawal to ascertain bilirubin levels and institute early care.  
Non-invasive, painless screening for jaundice by use of transcutaneous bilirubinometry is the 
standard of care for term and near term neonates 10,11. Preterm neonates are susceptible to 
bilirubin encephalopathy at lower serum bilirubin level hence; despite some studies showing 
good correlation 18-20 the pursuit for more accurate screening test has continued to be 
explored.  
The majority of studies using transcutaneous bilirubinometers have used the forehead and the 
sternum. We could find no literature on the use of the interscapular area.  
The purpose of this study was to establish the correlation between transcutaneous and serum 
bilirubin levels among preterm neonates <35weeks gestational age and its utility as a 
screening tool in the South African preterm population.  
Ethical approval: Ethical approval was obtained from the Human Research and Ethics 
Committee of  the University of Cape Town  and written consent was obtained from parents 
of study participants. 
Methods 
Setting: This study was conducted at Groote Schuur Hospital which is a level III neonatal 
care unit. The unit admits 200 neonates per month 10% weighing < 1500grams at birth. 
Study population: Preterm neonates of gestational age < 35 weeks who were < 8 days old in 














eligible. Eligible neonates who had poor perfusion (capillary refill >3 seconds) were 
excluded. 
Sample size: Computed sample size for positive and negative predictive value assuming 
transcutaneous bilirubin had a sensitivity of 80% in predicting need to start photo therapy 
with 95% confidence, the sample size need to demonstrate this with power of 90% was 122. 
Procedure: A cross sectional study was conducted between May 2012 and September 2012. 
Of the 306 preterm neonates <35 weeks gestational age admitted to the unit, 122 were 
enrolled for the study, see figure 1.  
Transcutaneous bilirubin (TcB) was measured on the forehead, chest (sternum) and 
interscapular area by the principal investigator using a Minolta JM103® bilirubinometer. 
These measurements were obtained within 30 minutes of blood withdrawal to establish serum 
bilirubin (TSB) levels. The bilirubinometer was calibrated once daily and used according to 
manufacturer’s instruction. An average of three measurements was recorded for each site. 
Data management: Baseline characteristics of study participants (gestational age estimated 
by early antenatal ultrasound or Ballard score, birth weight, and gender) were captured. Time 
of blood drawing for measuring serum bilirubin level, transcutaneous bilirubin 
measurements, total serum bilirubin level and phototherapy line were entered into data 
capturing sheet. Data was entered into Microsoft excel 2010 package then transferred to 
STATA version 11 for analysis. P value <0.05 was considered significant and confidence 
interval of 95% was used. 
Statistical methods: Shapirow wilk w test was used to classify distribution of data. 
Spearman’s correlation was computed for the different TcB’s, and using 2x2 tabulation with 
point of interest being initiation of phototherapy the sensitivity, specificity, positive and 
















Results: The median gestational age of the study participants was 31 weeks (range: 24-
34weeks), the median birth weight was 1242 grams (range: 608- 2560grams), 32 (26.2%) of 
study participants were small for gestational age (weight < 10th centile for gestational age), 
the median age when blood was drawn for serum bilirubin measurement was 21 hours (range: 
4- 136hours) 65.5% of these were obtained within the first 24 hours, and the median serum 
bilirubin was 81.5µmol/l (range: 25- 229µmol/l). Ninety four percent (94%) of study 
participants’ skin colour was described as pink and the rest as red. Table 1 shows baseline 
characteristics of study participants. 
TcB from sites studied (forehead, chest and interscapular) had statistically significant 
correlation with total serum bilirubin. The site with highest correlation coefficient was the 
chest (Cr 0.929 p<0.001). Table 2 shows correlation and difference between TSB and TcB. 
The correlation coefficients did not differ significantly between study participants of 
gestational age ≤ 30 weeks and those > 30 weeks. T ble 3 show correlation and difference 
between TSB and TcB at different gestational ages. 
The difference between TSB and TcB’s ranged from -86µmol/l to +51µmol/l with one outlier 
in whom the interscapular TcB underestimated TSB by 118µmol/l. Interscapular TcB tended 
to overestimate TSB. 
Graph 1 shows the correlation of transcutaneous and serum bilirubin at different TSB levels. 
From the graph it is evident that there was a tendency for TcB to underestimate TSB at low 
TSB levels and to overestimate at high levels. 
With respect to initiating phototherapy, the interscapular site had the highest sensitivity 
(93.9%). Table 4 shows sensitivity, specificity and false negative rates of transcutaneous 
bilirubin. The chest had the highest specificity (94.6%) while the interscapular area had the 
lowest false negative rate (6.06%). 
From the Receiver Operative Curve, the area under the curve for all the three sited were 














and interscapular site had sensitivities of 97%, 95.5%, and 95.5% respectively and 
specificities of 39.3%, 41% and 35.7% respectively, see figure 2, table 5 and 6. 
Discussion:	  The correlation coefficient of forehead TcB of 0.904 (p<0.001) found in this 
study was higher than that described by other studies 15,17,20,60 while the correlation 
coefficient of chest (sternum) TcB of 0.929 (p<0.001) is comparable to the finding of 
Schmidt et al over the sternum 0.79 to 0.92 (p<0.001)36. 
The correlation coefficients for forehead and chest TcB’s were higher among neonates of 
gestational age ≤ 30 weeks compared to those > 30 weeks. Although Knupfer et al using 
Bilicheck 15 found an increased discrepancy between serum bilirubin and forehead TcB with 
reducing gestational age, Ebbesen et al 60 using Minolta JM 103® found no association. 
Schmidt et al demonstrated an increase correlation of sternal TcB with decreasing gestational 
age 36. 
The discrepancy in correlation of forehead and total serum bilirubin may be due to the fact 
that the forehead is continuously exposed to ambient light hence results varying from infant 
to infant.  
The interscapular site has previously not been studied. This study included this site for two 
reasons:  firstly it is often shielded from ambient light and secondly the interscapular area is 
one of the areas where subcutaneous fat is first deposited 61. The correlation coefficient of 
interscapular TcB was 0.859 (p<0.001),but for one of the study participants interscapular TcB 
significantly underestimated TSB by 118µmol/l. When this neonate was excluded from the 
analysis the correlation was 0.89 (p<0.001). 
The correlation of interscapular TcB among neonates of gestational age ≤ 30 weeks was 
0.892 (p<0.001) and 0.844 (p<0.001) in those > 30 weeks.  
 














 - 86 to + 44 µmol/l, and - 52 to +48µmol/l respectively. These differences did not vary much 
when study population was stratified by gestational age of ≤ 30 or > 30 weeks. Twenty one 
21 (17.2%) of forehead and 9 (7.3%) of chest TcB overestimated while 24 (19.7%) of 
forehead and 32 (26.2%) of chest TcB underestimated TSB by >20µmol/l.  
Similar to findings from this study, other studies using different transcutaneous 
bilirubinometers have also reported wide differences between TSB and TcB’s measured over 
forehead and chest 15-17,20 with an overall tendency of forehead and chest TcB to 
underestimate the TSB. The reason for this is not clear but if might have to do with light 
exposure to the forehead and scarcity of subcutaneous fat in the sternal area.  
The difference between TSB and interscapular TcB in this study was -80 to +51µmol/l with 
one outlier in whom the TcB underestimated TSB by 118µmol/l. This difference did not vary 
much when study population was stratified by gestational age of ≤ 30 or > 30 weeks. 
Twenty nine 46 (37.7%) of interscapular TcB overestimated while 11 (9.0%) underestimated 
TSB by >20µmol/l. No study has previously assessed this site. It appears that the 
interscapular TcB tends to overestimate TSB with fewer cases underestimated compared to 
the forehead and the chest sites. The reason might be that this site has more adipose tissue. 
In accordance with Groote Schuur Hospital / South African Guidelines 48, phototherapy is 
commenced when serum bilirubin level is at phototherapy line or ≤ 20µmol/l below the line. 
During data analysis this was put into consideration. Total serum bilirubin ≤ 20µmol/l within 
phototherapy line, at phototherapy line or above phototherapy line was categorized as an 
indication for phototherapy. 
Table 4 shown sensitivity, specificity and false negative rates for using transcutaneous 
bilirubin as a trigger to start phototherapy. The sensitivity of forehead transcutaneous 
bilirubin in identifying study participants in need of phototherapy was 80.8% and comparable 














Knupfer et al found an increase in sensitivity with an increase in gestational age similarly our 
study found the same.  
From this study it seems that the chest was the poorest site of choice as many participants 
would not receive phototherapy when they actually needed it (30.3%). No study that we came 
across looked at sensitivity and specificity of the chest (sternum) transcutaneous bilirubin in 
determining need to initiate phototherapy without setting a cut off value.  
The interscapular TcB had the highest sensitivity in identifying study participants in need of 
phototherapy (93.9%) and it wrongly mislabelled 6.06% of those in need of phototherapy. At 
a relatively higher cutoff value of 52umol/l intescapular TcB had a high sensitivity of 95.5% 
but low specificity of 35.7% although at this same cut off value forehead and chest TcB’s had 
lower sensitivities of 92.4 and 84.8% respectively. At lower cutoff values the interscapular 
TcB maintained a higher sensitivity compared to the forehead and chest. No study has 
previously had a look at the interscapular site. It is a highly vascular site and one of the first 
sites where adipose tissue is deposited 61. It is also often shielded from ambient light. All 
these characteristic make this site a favourable one for transcutaneous bilirubinometry. 
 
Study Limitations 
1. Transcutaneous bilirubin measurements were obtained by the principal investigator who 
ensured that the Minolta JM 103® bilirubinometer was calibrated and followed 
manufacturers’ instruction. Under daily clinical practice if these are not observed the results 
might be highly varied. 
2. Highest total serum bilirubin obtained was 229µmol/l, so the performance of this device at 
much higher serum bilirubin levels is not known and cannot be extrapolated. 
3. These results only reflect the Minolta JM 103® bilirubinometer and these results cannot be 















Conclusion: TcB’s from  the sites assessed correlated significantly with TSB. The sensitivity 
of interscapular TcB in identifying preterm neonates who need phototherapy increased with 
increasing birth weight. The interscapular site is safe for jaundice screening of preterm 
neonates using Minolta JM 103® bilirubinometer.  
What is already known on this subject 
Although transcutaneous bilirubin measured from the forehead and sternum significantly 
correlate with the total serum bilirubin level, they have a tendency to underestimate total 
serum bilirubin levels. 
The use of transcutaneous bilirubin screening is currently not recommended for preterm 
neonates < 35 weeks gestational age. 
 
What this study adds  
This study has shown that the interscapular TcB tends to slightly overestimate total serum 
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APPENDIX 1: Informed consent form 
Title of study: Correlation between transcutaneous bilirubin and total serum bilirubin 
levels among preterm neonates at Groote Schuur hospital 
 
Dr. Abdallah Yaser from the Department of Neonatology is conducting a study in babies born 
before 35 weeks of pregnancy. He wants to find out how the level of yellow pigment 
(bilirubin) in skin compares to that in blood among these babies. We are approaching you for 
your consent in order to include your baby in the study. 
Introduction: 
The majority of babies born prematurely (<37 weeks of gestation) are at risk of turning 
yellow. This yellow discoloration is from breakdown of red blood cells which can be normal 
in newborn babies. The yellow pigment is normally broken down in the liver which tends to 
be less prepared among premature babies and this places premature babies at risk of turning 
yellow. High levels of yellow pigment (bilirubin) in blood can easily reach the brain and is 
known to cause brain damage. In order to prevent this blood is usually taken from babies to 
measure the amount of bilirubin and if found to be high th  babies are placed under special 
lights. In order to reduce taking blood from babies for this purpose a special device has been 
developed that measures the amount of bilirubin in the skin. In term babies this method has 
been proved to be good. Using this method has not been studied among premature babies in 
South Africa yet this might help reduce number of pricks our preterm neonates suffer and 
also reduce amount of blood they lose 
Purpose: The aim of the study is to find out how yellow pigment (bilirubin) measured by 
skin device compares to that measured in blood among preterm neonates <35weeks 
gestational age. 
Procedure: Only children born <35weeks gestational age in whom blood has been taken to 
measure yellow pigment (bilirubin) will be involved in this study. If your child is enrolled we 
will use the device for measuring yellow pigment in the skin on his/her forehead, chest and 
back. Your child will continue to receive care in line with hospital guidelines. 
Risks: There are no risks associated with the procedure your child will undergo. The 
procedure compares to gentle press with a finger. There will be no blood loss during the 
procedure. 
Benefits: Although this study might not benefit your child directly, we believe the findings of 














premature babies. If the method is established to be good, premature babies will be spared 
from pricks and blood loss. 
Costs: You will not be paid any incentive for your child’s participation. You will not be 
charged for the tests this study will be using. 
Patients’ right: Your child’s participation will be voluntary, and you have the right to refuse 
participating in the study. Your refusal to participate will not affect the care your child will 
receive. You have the right to know results obtained from your child.  
Confidentiality: All information from you and your child including laboratory results will be 
kept confidential and will be used for research purposes only. Only information that we think 
will improve the care your child receives will be released to the doctors attending to your 
child.  
Contact persons: If you have more questions and information that you may need 
clarification on, contact the following at any time: 
Principal investigator, Dr. Abdallah Yaser, Tel: +27797027500,  
                                    E-mail: yasam7862002@yahoo.com 
Dr. Natasha Rhoda, Tel: +27837000423, E-mail: Natasha.rhoda@uct.ac.za 
Dr. Lloyd Tooke, Tel: +27834562575, E-mail:Lloyd.tooke@uct.ac.za 
Department of Neonatology, Groote Schuur Hospital. 
If you want to know about your right and your child’s rights, contact the Chairman Human 
Research and Ethics Committee; 
Prof. M Blockman Tel: +27214066626. 
 
Statement of consent: The purpose and nature of this study has been explained to me and I 
understand that my child’s participation in this study is voluntary and that no consequences 
will result if I refuse to participate. I understand that some tests will be carried out; I have the 
rights to know the results. I…………………………………………………. (Mother) do 
hereby consent for my child to participate in the above study.  
Sign/thumb (mother) ………………………………………Date………………………….. 
























Date and time of birth……………………………  Mode of delivery………………………… 
Reason for preterm birth……………………………….. 
Steroid mature…………………………………………… 
Birth weight…………… Sex.............. Skin colour...................... Ethnicity…………………… 
Ballard score…………………………………..  Early U/S gestational age est……………….. 
Age in hours when TSB taken……………………………….. 
Reason for TSB request………………………………………… 
Photo line…………………………………….. Exchange line…………………………. 
TcB result     Forehead………………… 
                     Chest.................................... 











































         
         
         
         
         
 
January and February 2012: Ethical approval  
March 2012: Final touches on paper work 
April to July 2012: Data collection 
August 2012: Data entry and statistical analysis 





















UNIVERSITY OF CAPE TOWN 
• 
14 May 2012 
HREC REF: 195/2012 
Dr A Yaser 
Neonatology 
H49,OMB 
Dear Dr Yaser 
Health Sciences Faculty 
Human Research Ethics Committee 
Room E52-24 Groote Schuur Hospital Old Main Building 
Observatory 7925 
Telephone [021] 406 6338 • Facsimile [021] 4 06 6411 
e-mail : shuretta.thomas@uct.ac.za 
PROJECT TITLE: CORRELATION BETWEEN TRANSCUTANEOUS BILIRUBIN AND TOTAL 
SERUM BILIRUBIN LEVELS AMONG PRETERM NEONATES AT GROOTE SCHUUR HOSPITAL. 
Thank you for responding to the issues raised by the Faculty of Health Sciences Human Research 
Ethics Committee in your letter dated 13th May 2012. 
It is a pleasure to inform you that the HREC has formally approved the above-mentioned study. 
Approval is granted for one year till the 30th May 2013. 
Please submit a progress form, using the standardised Annual Report Form if the study continues 
beyond the approval period. Please submit a Standard Closure form if the study is completed within 
the approval period. 
(Forms can be found on our website: www.health.uct.ac.za/research/humanethics/forms) 
Please note that the ongoing ethical conduct of the study remains the responsibility of the principal 
investigator. 
Please quote the HREC. REF in all your correspondence. 
Yours sincerely 
Lio&01 db/1h. 
PROFESS~R M BLOctkMAN 
()O CHAIRPERSON. HSF HUMAN ETHICS n Federal Wide Assurance Number: FWA00001637. 
Institutional Review Board (IRB) number: IRB00001938 
This serves to confirm that the University of Cape Town Human Research Ethics Committee complies 
to the Ethics Standards for Clinical Research with a new drug in patients, based on the Medical 
Research Council (MRC-SA), Food and Drug Administration (FDA-USA), Internationa l Convention on 
Harmonisation Good Clinical Practice (ICH GCP) and Declaration of Helsinki guidelines. 
T he Human Research Ethics Committee granting this approval is in compliance with the ICH 
Harmonised Tripartite Guidelines E6: Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) 































































306 preterm neonates  
Less than 35 weeks gestational age 
admitted to GSH 
213 Eligible 
93 not eligible, Serum 
bilirubin not requested  
122 Enrolled 
91 excluded because: 
-19No consent 






















Table 1. Baseline Characteristics of study participants 
Variables                            Frequency (122)                       percentage (%) 
Sex        Female                                            66                                             54.0 
              Male                                                56                                             46.0 
 
Birth weight    ≤1000grams                         30                                             24.6 
                        1001-1499grams                   62                                             50.8 
                         ≥1500grams                         30                                             24.6 
 
Gestational age  ≤30 weeks                         51                                             41.8 
                            >30weeks                          71                                             58.2 
 
Steroid maturity 2doses                              59                                             48.4 
                            <2doses                             63                                             51.6 
 
Age serum bilirubin done 
                           ≤ 12 hours                          30                                             24.7 
                            13-24hours                        50                                             41.0 
                            25-36hours                        12                                               9.8 
                            35-48hours                          9                                               7.3 
                            >48hours                           21                                             17.2 
 
Serum bilirubin levels* 
                            <80micromoles/l              58                                              47.5 
                      80 – 150micromoles/l            51                                              41.8 
                           >150micromoles/l             13                                              10.6 
*maximum serum bilirubin 229µmol/l 
 
Table 2: Table of correlation and difference between total serum bilirubin and 
transcutaneous bilirubin from the three body sites 
Test Correlation  
co-efficient‡(Cr) 
Difference  





TcB forehead 0.904 (p<0.001) -86 – 44µmol/l 17.2/19.7 
TcB Chest 0.929 (p<0.001) -52 – 48µmol/l 7.3/26.2 
TcB Interscapular 0.859 (p<0.001) -80 – 118µmol/l 37.7/9.0 
‡Spearman’s correlation 
TSB - Total serum bilirubin 
















Table 3: Table of correlation and difference between total serum bilirubin and 
transcutaneous bilirubin from the three body sites with respect to gestational age.  





TcB Forehead  ≤ 30 weeks 









TcB Chest   ≤ 30 weeks 









TcB Interscapular ≤ 30weeks 









(One outlier 118µmol/l) 
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Table 4: Table of sensitivity, specificity and false negative rate of transcutaneous 
bilirubin from the three body site with respect to initiation of phototherapy 

































False Negative rate  
TcBf                                                      














95% confidence interval. 
TcBf- Transcutaneous bilirubin forehead 
TcBc- Transcutaneous bilirubin chest 






Fig 2 ROC 
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Source of the Curve 
TcB Forehead  
(TcBF) 






















Table 5. Area under the Curve 
 






Lower Bound/ Upper Bound 
TcB Forehead (TCBF) .726 .047 .000 .635 .817 
TcB Chest (TCBC) .697 .050 .000 .600 .795 
TcB Interscapular (TCBI) .714 .048 .000 .620 .808 
 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
 
 
Table 6. Sensitivities and specificities of TcB’s at best cutoff values for each site 
 
Cutoff TcB Forehead 
 
TcB Chest TcB Interscapular 
 Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity 
52.0umol/l 92.4% 53.0% 84.4% 47.2% 95.5% 35.7% 
42.0umol/l 97.0% 39.3% 92.4% 45.7% 97.0% 33.0% 
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